INFECTIOUS DISEASE AEROBIOLOGY CORE

传染病有氧生物学核心

• 批准号: 8358141
• 负责人: CHAD J. ROY
• 金额: $ 3.72万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8358141
• 关键词: Aerosols; Animals; Area; Biological; Burkholderia; Burkholderia pseudomallei; Centers for Disease Control and Prevention (U.S.); Chad; Communicable Diseases; DNA; Disease model; Drug Evaluation; Eastern Equine Encephalitis Virus; Engineering; Extramural Activities; Funding; Goals; Grant; Individual; Infection; Infectious Agent; Laboratories; Learning; Location; Monkeypox virus; Mycobacterium tuberculosis; National Center for Research Resources; Organism; Oryctolagus cuniculus; Pharmacologic Substance; Powder dose form; Primates; Principal Investigator; Research; Research Infrastructure; Research Personnel; Resources; Ricin; Rickettsia prowazekii; Rodent; Scientist; Source; Staphylococcal Enterotoxin B; System; Therapeutic; Toxin; United States National Institutes of Health; Vaccines; Viral; base; cost; influenzavirus; microbial; model development; nonhuman primate; novel; pathogen; research study; vaccine efficacy

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The infectious disease aerobiology core has become a productive scientific core within the TNPRC. The core has expanded its technical capabilities required for bioaerosol characterization and aerosol challenge of diverse infectious agents by the addition of an automated version of the bioaerosol exposure system (in 2010) and the addition of the aerobiology suite within the BSL-3 envelope in the new regional biosafety laboratory on the campus of the TNRPC. The core has also expanded its functional capability to deliver dry powder pharmaceutical grade therapeutics in conjunction with drug evaluation studies that are ongoing as part of the core. The exposure facility operated under the aerobiology core is now located in two locations at the TNPRC within CDC-approved select agent registered biosafety level 3 (BSL-3) areas. In addition to nonhuman primate aerosol exposure capability, the core also performs aerosol exposures on smaller animals. Establishment of this core provides a unique resource that enables investigators to perform key experiments to further understand the biological basis of airborne-transmitted infectious diseases. In addition to the core director Dr. Chad J. Roy, the core is staffed by Dr. Satheesh Sivasubrahamni who serves as a fulltime research scientist and Ms. Rachel Redmann who serves as the core aerosol engineering technician. In the past year, the core has been consistently engaged in collaborative research studies with both intramural and NIH-funded extramural investigators; the number of extramural users of the core now exceeds twelve collaborating laboratories. In 2010, the core performed 93 individual nonhuman primate exposures using the following pathogens: staphylococcal enterotoxin B (SEB), ricin toxin, Eastern Equine Encephalitis virus, Burkholderia pseudomallei, Rickettsia prowazekii, monkeypox virus, influenza virus, and Mycobacterium tuberculosis. The core also performed 276 individual rabbit exposures (96 individual infections and 180 therapeutic aerosol treatments), and 168 rodent exposures (128 infections and 40 treatments). In addition to the animal exposures and treatments, the core performed 48 microbial characterization assessments with a variety of pathogenic organisms and toxins as well as therapeutic biologics and pharmaceuticals. Attested by the numbers shown for this past year, the majority of core collaborative research involves experimental aerosol infection as an essential component of studies broader research goals such as disease model development or vaccine efficacy. In addition to experimental infection, the core is instrumental in providing aerosol characterization for novel pathogenic agents (e.g., RSV) and aerosol viability assessment for viral-vectored vaccine products. Requests for microbial efficiency studies using novel microbial agents (e.g., naked DNA, Burkholderia sp.) have also continued to increase as collaborative laboratories learn of the capabilities made available through this core.

该副本是利用资源的众多研究子项目之一 由NIH/NCRR资助的中心赠款提供。对该子弹的主要支持 而且，副投影的主要研究员可能是其他来源提供的 包括其他NIH来源。 列出的总费用可能 代表subproject使用的中心基础架构的估计量， NCRR赠款不直接向子弹或副本人员提供的直接资金。 传染病的特技生物学核心已成为TNPRC中的生产科学核心。 该核心通过添加自动化版本的生物Aerosol暴露系统（2010年）以及在新区域生物适用于Tnrpc Campus的新区域生物适用实验室中的BSL-3信封内添加了自动化版本，扩大了多种传染性代理商的生物Aerosol表征和气溶胶挑战所需的技术能力。 该核心还扩大了其功能能力，可以与作为核心的一部分进行的药物评估研究结合使用干粉药级治疗。 现在，在CDC批准的Select Select Agent注册生物安全3级（BSL-3）区域内的TNPRC的两个位置位于TNPRC的两个位置。 除非非人类灵长类动物气溶胶的暴露能力，核心还对较小的动物进行气溶胶暴露。 建立该核心提供了一种独特的资源，使研究人员能够执行关键的实验，以进一步了解空气传播的传染病的生物学基础。 除核心主任查德·J·罗伊（Chad J. Roy）博士外，核心还由Satheesh Satheesh Sivasubrahamni博士组成，他是一名全日制研究科学家和Rachel Redmann女士，担任核心Aerosol工程技术员。 在过去的一年中，核心一直与壁内和NIH资助的壁外研究人员进行合作研究。现在，核心的壁外用户数量超过了十二个合作实验室。在2010年，核心使用以下病原体进行了93个单独的非人类灵长类动物暴露：葡萄球菌肠毒素B（SEB），瑞奇蛋白毒素，东马脑炎病毒，伯克霍尔德氏菌，伯克霍尔德氏菌，Rickettsia prowazekii，monkeypox virus virus，thaterc virus，thaleenza virus，thalenza virus和myc cirter and Myc and Myc and Mycc。 该核心还进行了276次单独的兔子暴露（96种个人感染和180种治疗性气溶胶处理）和168次啮齿动物暴露（128种感染和40种治疗方法）。 除了动物的暴露和治疗外，核心还通过多种致病生物和毒素以及治疗生物制剂和药物进行了48个微生物表征评估。 在过去的一年中所显示的数字证明，大多数核心协作研究都涉及实验性气溶胶感染，这是研究目标的重要组成部分，例如疾病模型开发或疫苗疗效。 除了实验感染外，该核心还可以为新型致病剂（例如RSV）和病毒载体疫苗产品的气溶胶生存力评估提供气溶胶表征。 随着协作实验室了解通过该核心提供的功能，使用新型微生物剂（例如裸体DNA，Burkholderia sp。）对微生物效率进行研究的要求也继续增加。